Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 146 recruiting now early-phase tilt #12 of 28,963 conditions

Lung Cancer: early-phase trial registry

146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #12 of 28,963 conditions by registered trial count.

430 US clinical trials · 146 currently recruiting · #12 of 28,963 conditions by registered trial count

Lung Cancer: 430 US clinical trials tracked, 146 recruiting.

Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.

Open enrollment, early-phase tilt

Lung Cancer has 430 registered US clinical trials, 146 of them open to new participants right now, about 34% of the total.

146
recruiting participants now
34%
of trials open to enrollment
23
in Phase 3-4 (later-stage)
36
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #12 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Cancer is recruiting below its size-band peers.

    146 of 430 indexed trials (34%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lung Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lung Cancer enrolment sits around 89 participants.

    Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.

  4. Lung Cancer research is mostly interventional.

    321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 185Phase 296Phase 322Phase 41

Open and recent trials

430 total, page 7 of 9

COMPLETED Phase 2 70 participants

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

ECOG-ACRIN Cancer Research Group

NCT00828009

COMPLETED NA 70 participants

Broccoli Sprout Extract in Preventing Lung Cancer in Smokers

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00255775

COMPLETED Phase 1 69 participants

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

NCT00032032

COMPLETED Phase 3 67 participants

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

Alliance for Clinical Trials in Oncology

NCT00040885

COMPLETED 67 participants

Development of a Clinical Trial Specific Question Prompt List

Memorial Sloan Kettering Cancer Center

NCT00662324

COMPLETED Phase 2 65 participants

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

NCT00798603

COMPLETED Phase 1 64 participants

ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer

Memorial Sloan Kettering Cancer Center

NCT00077246

COMPLETED Phase 1 64 participants

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

University of California, Davis

NCT00408499

COMPLETED Phase 2 63 participants

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

NCT00413283

COMPLETED NA 62 participants

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

Massachusetts General Hospital

NCT02871115

COMPLETED Phase 1 62 participants

Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously

The Netherlands Cancer Institute

NCT01543672

COMPLETED Phase 1 61 participants

Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

Yale University

NCT02407171

COMPLETED Phase 2 60 participants

S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

SWOG Cancer Research Network

NCT00002969

COMPLETED NA 60 participants

Improving Supportive Care For Patients With Thoracic Malignancies

Palo Alto Veterans Institute for Research

NCT03216109

COMPLETED 59 participants

Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies

Dana-Farber Cancer Institute

NCT00973440

COMPLETED Phase 2 59 participants

Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Radiation Therapy Oncology Group

NCT00087438

COMPLETED Phase 1 56 participants

Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT00049218

COMPLETED NA 54 participants

Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy

University of California, San Francisco

NCT05342675

COMPLETED NA 52 participants

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Washington University School of Medicine

NCT05427214

COMPLETED Phase 2 51 participants

Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

NCT00005059

COMPLETED Phase 2 50 participants

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Vanderbilt-Ingram Cancer Center

NCT00984542

COMPLETED 50 participants

Olympus - 19-gauge Needle

Duke University

NCT03270670

COMPLETED 50 participants

Cigarette Smoking and Oral Microbiota

National Cancer Institute (NCI)

NCT01862809

COMPLETED Phase 2 50 participants

Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

University of Washington

NCT00425646

COMPLETED NA 49 participants

Tumor Markers in Lung Cancer: DCAMLK-1LK-1

University of Oklahoma

NCT01578018

COMPLETED Phase 2 48 participants

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Stanford University

NCT00323869

COMPLETED Phase 2 46 participants

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00276588

COMPLETED Phase 2 46 participants

S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors

SWOG Cancer Research Network

NCT00062439

COMPLETED NA 46 participants

Women Helping Women - Lung Cancer Screening

University of Florida

NCT04983134

COMPLETED NA 46 participants

Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

NCT00089310

COMPLETED NA 44 participants

Decision Counseling Program in Increasing Shared Decision Making and Clinical Trial Participation in Patients With Stage 0-IV Lung Cancer (Free to Breathe)

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT03820557

COMPLETED 44 participants

Microbiome in Lung Cancer and Other Malignancies

Taher Abu Hejleh

NCT03688347

COMPLETED NA 44 participants

Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

New Mexico Cancer Research Alliance

NCT00832780

COMPLETED Phase 2 44 participants

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Memorial Sloan Kettering Cancer Center

NCT00807573

COMPLETED Phase 1 43 participants

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

H. Lee Moffitt Cancer Center and Research Institute

NCT01859026

COMPLETED Phase 2 43 participants

Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers

Jian-Min Yuan, MD

NCT03232138

COMPLETED Phase 2 42 participants

Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Case Comprehensive Cancer Center

NCT00006017

COMPLETED 42 participants

Health Communication in Families

Memorial Sloan Kettering Cancer Center

NCT00597961

COMPLETED Phase 2 42 participants

Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT00293280

COMPLETED Phase 2 40 participants

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

St. Vincent Medical Center - Los Angeles

NCT00002475

COMPLETED Phase 2 40 participants

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Memorial Sloan Kettering Cancer Center

NCT02525653

COMPLETED Phase 2 40 participants

Ketamine In Thoracic Surgery (KITS) Trial

Duke University

NCT00504725

COMPLETED NA 40 participants

Mindfulness Therapy for Individuals With Lung Cancer

Michigan State University

NCT01565980

COMPLETED Phase 2 38 participants

Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

M.D. Anderson Cancer Center

NCT00984997

COMPLETED Phase 2 38 participants

Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia

Barbara Ann Karmanos Cancer Institute

NCT00056004

COMPLETED Phase 1 38 participants

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

BioNTech US

NCT03380871

COMPLETED Phase 2 37 participants

Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

University of Virginia

NCT00114192

COMPLETED Phase 2 37 participants

Cabozantinib in Advanced Solid Malignancies

Massachusetts General Hospital

NCT01588821

COMPLETED 37 participants

Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

Vanderbilt-Ingram Cancer Center

NCT00899457

COMPLETED 37 participants

Assess the Variability of Uni-Dimensional, Bi-Dimensional, and Volumetric CT Scan Measurement of Non-Small Cell Lung Cancer Tumors

Memorial Sloan Kettering Cancer Center

NCT00579852

← Previous Page 7 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 85
Phase 2 96
Phase 3 22
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Lung Cancer right now

146 recruiting of 430 indexed (34% open).

Phase mix: 23 late (III/IV) vs 181 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (36 trials), 9 others listed. 50 shown below, recruiting first. #12 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Lung Cancer?

PlainTrial tracks 430 US clinical trials for Lung Cancer, of which 146 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Lung Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.